60 Degrees Pharmaceuticals Raises $1M in At-the-Market Private Placement — 60 Degrees Pharmaceuticals, Inc.

Event summary

60 Degrees Pharmaceuticals raised $1M through a private placement of 574,713 shares of common stock (or pre-funded warrants) at $1.74 per share.
The offering includes Series A and Series B warrants with exercise prices of $1.49 per share, exercisable upon issuance.
Proceeds will be used for working capital and general corporate purposes.
H.C. Wainwright & Co. acted as the exclusive placement agent.

The big picture

60 Degrees Pharmaceuticals' $1M private placement reflects a strategic move to bolster working capital amid ongoing operational challenges. The deal underscores the company's focus on securing non-dilutive funding while navigating regulatory hurdles and commercializing its lead product, ARAKODA. The broader biotech sector continues to grapple with financing constraints, making such placements critical for sustaining R&D and market expansion.

What we're watching

Financial Stability: How the $1M infusion will impact 60 Degrees' liquidity and ability to fund operations.
Warrant Exercise: The pace at which Series A and Series B warrants are exercised, affecting dilution and capital structure.
Regulatory Approvals: Whether the company can secure additional FDA approvals to expand its product portfolio beyond malaria prevention.